Fig. 1: Overview of NeoPrecis for tumor neoantigen assessment. | Nature Communications

Fig. 1: Overview of NeoPrecis for tumor neoantigen assessment.

From: NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes

Fig. 1: Overview of NeoPrecis for tumor neoantigen assessment.The alt text for this image may have been generated using AI.

The workflow begins with the computation of neoantigen-related multi-dimensional metrics, including neoantigen abundance, MHC presentation, and TCR recognition, for each protein-altering somatic mutation. These metrics are subsequently integrated to derive mutation-centric immunogenicity scores. Finally, a tumor-centric immunogenicity score is generated using a framework designed to map the neoantigen landscape considering neoantigen immunogenicity and tumor clonality.

Back to article page